
Macipah10 mg
Unimed Unihealth MFG. Ltd.
Established / FDA-Approved Indication macitentan is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adults and more.
macitentan is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adults, to delay disease progression and reduce the risk of hospitalization for PAH. Disease progression events in the pivotal trial included death, atrial septostomy, lung transplantation, initiation of intravenous or subcutaneous prostanoid therapy, and worsening of PAH.
macitentan may be used as monotherapy or in combination with other approved PAH therapies (for example, phosphodiesterase-5 inhibitors), consistent with current pulmonary hypertension treatment guidelines that support combination therapy for many patients.
macitentan is not approved and not recommended for other forms of pulmonary hypertension (e.g., WHO Groups 2, 3, 4, or 5) or for any indication outside PAH; such use would be off-label and is not supported by adequate evidence.
| Population | Recommended dose of macitentan |
|---|---|
| Adults with PAH | 10 mg orally once daily, with or without food |
| Mild-moderate hepatic impairment (Child-Pugh A/B) | No dose adjustment required |
| Severe hepatic impairment (Child-Pugh C) | Not recommended; not studied |
| Mild-moderate renal impairment | No dose adjustment required |
| Severe renal impairment (including dialysis) | Not studied; use with caution |
The standard macitentan tablet has not been established as safe and effective in patients under 18 years of age. A dispersible tablet formulation of macitentan with weight-based dosing has been evaluated and authorized in some markets for children 2 years of age and older with PAH; such use should be guided by a pediatric pulmonary hypertension specialist. See Use in Special Populations.
If a dose of macitentan is missed, it should be taken as soon as remembered on the same day; if it is almost time for the next dose, the missed dose should be skipped. Do not double the dose.
Common side effects of macitentan (occurring more often than with placebo) include:
Less common but serious effects include liver enzyme elevation or hepatotoxicity, severe anemia requiring transfusion, and pulmonary edema in patients with underlying pulmonary veno-occlusive disease (see Precautions and Warnings).
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.